Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002032
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex MAC Bacteremia in AIDS Patients With CD4 Counts or 200 A Double-Blind Placebo-Controlled Trial
Sponsor:
Pharmacia
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex MAC Bacteremia in AIDS Patients With CD4 Counts or 200 A Double-Blind Placebo-Controlled Trial
Status:
COMPLETED
Status Verified Date:
1992-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objectives of this trial are To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex MAC bacteremia in AIDS patients with CD4 counts less than or equal to 200 cellsmm3 To investigate the incidence of MAC in these patients A secondary objective is to compare clinical response quality of life Karnofsky and survival between these two groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 087023-999 | None | None | None |